The Rous-associated virus 1 env gene, which encodes the envelope gp85 and gp37 glycoproteins, was isolated and inserted in place of the v-erbB oncogene into an avian erythroblastosis virus-based vector, carrying the neo resistance gene substituted for the v-erbA oncogene, to generate the pNEA recombinant vector. A helper-free virus stock of the pNEA vector was produced on an avian transcomplementing cell line and used to infect primary chicken embryo fibroblasts (CEFs) or quail QT6 cells. These infected cells, selected with G418 (CEF/NEA and QT6/NEA, respectively) were found to be resistant to superinfections with subgroup A retroviruses. The CEF/NEA preparations were used as a cell-associated antigen to inoculate adult chickens by the intravenous route compared with direct inoculations of NEA recombinant helper-free viruses used as a cell-free antigen. Chickens injected with the cell-associated antigen (CEF/NEA) exhibited an immune response demonstrated by induction of high titers of neutralizing antibodies and were found to be protected against tumor production after Rous sarcoma virus A challenge. Conversely, no immune response and no protection against Rous sarcoma virus A challenge were observed in chickens directly inoculated with cell-free NEA recombinant virus or in sham-inoculated chickens.
Infections of chickens with avian retroviruses are widespread, as evidenced by the synthesis of specific antibodies in most chicken flocks (12, 14, 31) . To keep flocks free from avian sarcoma and leukosis viruses, eradication methods are applied by eliminating all viremic and serologically positive birds, essentially by eliminating hens that excrete virus in their eggs (4, 36) . Several approaches have been used simultaneously to provide resistance to avian retrovirus infections. Studies have shown that chickens inoculated with either pathogenic avian leukosis virus or low doses of Rous sarcoma virus (RSV) produce an immune response and fewer tumors after RSV challenge with the same subgroup (16, 20, 23) . Similarly, immunization of chickens has been obtained by using purified envelope glycoproteins (gp85 and gp37) that induce both an immune response, as evidenced by detection of virus-neutralizing antibodies (1) , and resistance to tumor production after subsequent RSV challenge (3) . Finally, a recombinant avian leukosis virus containing structural genes (gag-pol and env), originating from subgroup A RSV, and the long terminal repeats from Rous-associated virus type 0 (RAV-0), corresponding to a naturally attenuated nonpathogenic endogenous virus from subgroup E (30), was inoculated into chicken embryos (18 days of incubation) or hatched chicks (21, 33) . Production of viral proteinspecific antibodies was detected in most chicks at 5 weeks postinoculation of the recombinant avian leukosis virus (21) . Moreover, significantly smaller tumors than those of shaminoculated controls were observed when these treated birds were RSV challenged (33 Pulawy Al., Partysantow 57, Poland.
We and other teams have recently reported the construction of avian packaging cell lines (6, 32, 34) that enable production of replication-defective avian leukosis virusbased vectors as helper-free virus stocks (5, 7, 19, 26, 27) . Therefore, these avian packaging cell lines would offer the opportunity to investigate avian vaccination approaches by using retroviral vectors obtained as ecotropic helper-free virus stocks. The purpose of this study was were deleted and the v-erbA oncogene was replaced by the bacterial neomycin resistance gene, to generate pTXN5' (2). pNL53 was derived from pTXN5' by insertion of the bacterial lacZ gene in place of the v-erbB oncogene (7, 19) .
Chicken lines. Brown Leghorn chickens (C/E) closely monitored for infection with ALSV were obtained from the Station de Pathologie Aviaire INRA Tours Nouzilly. This flock, maintained in isolation, was constantly monitored for avian sarcoma and leukosis virus infections. All chickens used in our experiments were obtained from this flock.
Construction of the pNEA vector. A 1.9-kb KpnI-AccI fragment containing the splice acceptor site and the env gene was isolated from plasmid pRAV-1 and then inserted between the KpnI and AccI sites of the pUC19 polylinker to generate the pUCenvA recombinant plasmid (see Fig. 1 ).
Partial digestion of the pUCenvA plasmid with EcoRI and
HindIII allowed a 1. Cells and culture conditions. QT6 is a chemically derived Japanese quail tumor cell line, kindly provided by C. Moscovici (25) . Haydee is a transcomplementing cell line derived from QT6, in which we inserted a RAV-1 packaging mutant containing the expressing the gag and pol retroviral genes, as well as the selectable bacterial hygromycin resistance gene (6) .
CEFs were prepared from C/E Brown Leghorn 10-day-old chicken embryos and grown as previously described (15) . Both QT6 cells and CEFs were grown in F10 medium supplemented with 5% calf serum and 1% chicken serum. The Haydee cell line was grown in the same medium containing 50 pg of hygromycin B (Boehringer Mannheim) per ml.
Recovery of NEA virions and virus titration. NEA plasmid DNA transfection into the Haydee cell line was performed as described by Kawai and Nishizawa (18) . Transfected cells were grown in medium containing 200 ,ug of G418 (GIBCO-BRL) per ml and 50 ,ug of hygromycin B per ml. At 10 to 15 days later, resistant colonies were submitted to the action of trypsin to produce a polyclonal culture. Helper-free virus stocks were then harvested from subconfluent Neor cells in fresh medium at 6 to 16 h later. Cell debris were removed by centrifugation (10 min, 3,000 rpm, 4°C), and the harvested supernatant containing the virus stock was cleared again by filtration through a 0.22-,um-pore-size membrane (Millipore).
The resulting helper-free virus stock was either used directly to infect a cell culture or stored at -70°C before use.
NEA helper-free virus stocks recovered from the Haydee/ NEA cell line were titrated through induction of resistance after infection of either QT6 cells or CEFs with various dilutions of virus stocks and selection of the infected cells with G418. Neor clones were scored to determine the virus titer expressed as resistance-forming units per milliliter.
Preparation of immunogen products. G418-resistant CEFs resulting from NEA virus infection (called CEF/NEA) were UV irradiated (4,000 R at 254 nm) and treated with trypsin, and dissociated cells were recovered in phosphate-buffered saline. Cells were then frozen and thawed before use. Uninfected CEFs, used as controls, were also UV irradiated and received the same treatment as CEF/NEA.
Immunization experiments. Three-month-old Brown Leghorn chicks were divided into four groups of 9 to 11 animals (see Table 1 ). with CEF/NEA antigen (group 2) revealed the presence of a high level of specific antibodies directed against subgroup A env glycoproteins. Conversely, sera from birds either directly inoculated with the NEA virus stock or sham inoculated with a noninfected CEF preparation were negative, as were those from noninoculated birds.
Serum neutralization test values obtained with sera collected 35 days after immunization from group 2 birds were used to plot neutralization curves of NL virus against serum dilutions as previously described (13) . From these curves, the ND50 for each serum was determined (Table 3 ). These results demonstrate that in sera of all of the birds except one (bird 4 [ Table 2 ]), the ND50 corresponded to high serum dilution values, two of them being higher than 1/8,000 per 10-1. Moreover, to determine the kinetics of neutralizing antibody production, ND50 values were determined every week (i.e., 15, 21, 28, and 35 days after immunization) for every serum from all of the birds of group 2 (Fig. 2) . The average curve showed a linear increase in neutralizing antibody production until the week 4, and the rate of production decreased during the last week.
Induction of protection against RSV challenge. Five weeks after the first immunization, all chickens were challenged with 103 tumor-forming units of RSV Schmidt-Ruppin strain A via wing web injection. The results in Table 1 demonstrate that all of the chickens immunized with a CEF/NEA preparation (group 2) were resistant to tumor production, while all of the other chickens (groups 1, 3, and 4) developed tumors, which progressively increased in size in most cases (Fig. 3) group A env glycoproteins and showed protection against tumor development, whereas no antibody production was observed in all sera of chickens of the other groups, which were not protected. It should be noted that tumor progressions were practically similar for groups 1 and 4 compared with group 3, in which greater tumor volumes were observed during the same period (Fig. 3) . Table 3 ). This humoral response was detectable 2 weeks after the first immunization treatment and increased progressively over the following weeks (Fig. 2) , until week 5 to 6. In contrast, no antibody response was observed in the seroneutralization test from sera of group 3 birds inoculated with the NEA virus. Several explanations may be given for expressing the env glycoproteins were rapidly excluded before they could be used to stimulate an effective immune response.
DISCUSSION
Resistance against tumor production after RSV challenge in all of the animals from group 2 illustrates the efficiency of such a modality of immunization. Indeed, no tumor production was observed in this group, although animal 4 (Tables 2  and 3 ) appeared to have fewer neutralizing antibodies in its serum. This animal produced less than 10% neutralizing antibodies compared with animals 5 and 8. We can conclude that in most cases, humoral responses induced by a cellassociated antigen produced a sufficient rate of neutralizing antibodies, ranging from 3 to 10 times higher than necessary to induce resistance to RSV challenge. In the other groups (1, 3, and 4), all of the birds had developed tumors which appeared 2 weeks after RSV challenge and then tumor volume increased progressively during the next weeks (Fig.  3) . No significant difference was observed between the tumor sizes of group 1 (sham-inoculated) and group 4 (noninoculated) birds after RSV challenge, while increased volumes of tumors were measured in group 3 birds (Fig. 3) . The reason for such large tumor sizes in animals directly inoculated with NEA virus compared with those in the other two groups (1 and 4) is unknown. In previous works, it has been reported that chickens either expressing endogenous viral gene ev2-producing RAV-0 virus or infected with the RAV-0 virus as embryos (on day 6 of incubation) became immunologically tolerant to further exogenous retrovirus infections by limiting immune responses (8) (9) (10) (11) 22) . In the Brown Leghorn line we used, we showed that four endogenous structures (evBL) are present and that some of them are expressed (29) . Taking into account the above-mentioned hypothesis, we suppose that evBL expression can also limit the immune response in birds inoculated with either a CEF/NEA preparation or NEA virus. It would be interesting to know whether birds from group 2, which produce a high titer of neutralizing antibodies, possess expressed endogenous structures.
Several previous approaches have been attempted to confer resistance to RSV challenge on chickens. In the most recent studies, using either purified glycoproteins encoded by the env gene, isolated by sedimentation (3), or an attenuated recombinant avian leukosis virus (21, 33) , researchers demonstrated that the conditions used stimulated an immune response capable of partially protecting birds against tumor production after RSV challenge. Our results demonstrated that cell-associated antigens are able to induce an efficient immune response correlated with highly efficient resistance to tumor production. In a mammalian retrovirus system, the ability of a cell-associated antigen to induce an immune response and protect animals against retrovirus infection was tested by using infection with a replication-competent retrovirus of either lymphoblastoid cells (17, 28) or an established bone marrow (BL-3) cell line (35) . However, all of the experiments done under these conditions produced both partial induction of an immune response and limited protection against retrovirus infection. These results could be explained by the occurrence of several viral antigens expressed from such infected cells, with some of them, for example, gag-encoded proteins, being more abundant than env-encoded glycoproteins. Consequently, the presence of other antigens could partially prevent the expected immune response against the envelope glycoproteins and thereby lead to a decrease in the neutralizing antibody level, which is correlated with reduced protection against retrovirus infection.
In conclusion, CEFs infected with a recombinant AEVbased vector produced as a helper-free virus stock, carrying and expressing the env gene of subgroup A, corresponded to an efficient immunogen preparation. Immunized chickens showed production of neutralizing antibodies and were protected against RSV challenge. These results demonstrated that expression of the env gene in CEFs produced a protein with its natural folded structure. Experiments are in progress to (i) determine whether the route of immunization can influence the efficiency of tumor resistance, as previously reported (1), and (ii) test our vaccination procedure on younger target chickens (hatched birds and 18-day-old embryos), as well as the subgroup specificity of protection. Moreover, in another work, we have successfully used similar approaches to induce protection against Newcastle disease virus (unpublished data).
